WeBrokr is a boutique M&A firm with extensive experience working with both buy-side and sell-side clients. Focused primarily on technology and web properties with valuations from $1m - $10m, and has also navigated larger software & technology acquisitions valued between $20-$75m.

•Supported clinical trial project management activities through all phases of a clinical trial.Therapeutic Experience• Acute on Chronic Liver Disease• Autoimmune Disease• Lysosomal Storage Disease• Oncology• Cell Therapy• Stem Cell / Solid Organ TransplantCTI Clinical Trial Experience • A phase I/II, 1- to 4-site, 39-patient, dose-escalation study in males and females aged 18 to 75 with R/R CD20+ diffuse large B-cell lymphoma• A global phase II, 34-site, 48-patient study to evaluate the efficacy of extracorporeal photopheresis (ECP) in conjunction with standard therapy in pediatric hematopoietic stem cell transplant (HSCT) patients with acute graft versus host disease (aGvHD)• A phase I, 8-site, 12-patient, open-label, single-dose, dose-ranging study to assess the safety and tolerability of xxx in patients with Mucopolysaccharidosis (MPS II)• A phase II, up to 8-sites, 161-patient study to evaluate the safety and efficacy of xxx in lung transplant ex-vivo lung perfusion patients• A phase III, 40-site, 380-patient study to evaluate the safety and efficacy of xxx in subjects with acute on chronic liver failure• A long-term follow up, 24 site, non-interventional safety monitoring study of patients treated in various cell therapy/oncology studies.